Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic

Medical Journal of Australia

Volumn 188, Issue 2, 2008, Pages 72-75

  Kidson Gerber, Giselle L ^a   Francis, Sally ^b   Lindeman, Robert ^c,d  

^a ST GEORGE HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; SIDEROPHORE;

ADULT; ARTICLE; AUSTRALIA; BLOOD TRANSFUSION; CARDIOMYOPATHY; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIABETES MELLITUS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; MALE; MEDICAL AUDIT; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEROLOGY; TERTIARY HEALTH CARE; THALASSEMIA MAJOR; AGE; BLOOD; ERYTHROCYTE TRANSFUSION; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; STATISTICS; THALASSEMIA; TIME;

ADULT; AGE FACTORS; AUSTRALIA; CARDIOMYOPATHIES; DEFEROXAMINE; DIABETES MELLITUS; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HEPATITIS B; HEPATITIS C; HUMANS; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATING AGENTS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PYRIDONES; RETROSPECTIVE STUDIES; SIDEROPHORES; THALASSEMIA; TIME FACTORS;

EID: 41149102394     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01525.x     Document Type: Article

References (10)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
2. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood 2004; 104: 34-39.
3. Australian Red Cross Blood Service. Quick reference guide: obtaining informed consent - blood and blood products. http://www.transfusion.com.au/TRANSFUSIONPOCKETGUIDES/ Pocket_RiskConsent.asp (accessed Nov 2007).
4. Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007; 92: 131-132.
5. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8: 543-547.
6. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761.
7. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2052.
8. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002; 288: 2868-2879.
9. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
10. Ward A, Caro J, Green T, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3.